Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Galapagos NV
Two US VCs have led a large $75m series B financing of Belgium’s AgomAb Therapeutics, which is gaining traction in developing antibodies that act on the HGF-MET pathway, potentially reversing fibrosis and allowing damaged tissues to regain function.
After a difficult spell for the Belgian biotech, positive interim data from two key studies looking at testicular toxicity concerns over filgotinib suggest a pathway for potential future US approval of the Gilead-partnered JAK inhibitor for IBD.
The Belgian biotech is pleased with the launch of its rheumatoid arthritis drug in Germany and the Netherlands and it has also secured a broad label from NICE.
Following a trio of high-profile setbacks, the Belgian biotech is looking to fill the gap between the European launches of its rheumatoid arthritis drug Jyseleca and its programs back in Phase II via in-licensing and M&A.
- Drug Discovery Tools
- Large Molecule
- Other Names / Subsidiaries
- Discovery Partners International
- Inpharmatica Ltd.
- Sareum Holdings plc.